Liu et al. reported A485, a p300/CBP inhibitor abrogated immune process and decreased the secretion of exosomal PD-L1 by blocking the transcription of CD274, which combined with the anti-PD-L1 antibody to reactivate T cells function for tumor attack [26]. Here, CD274 is linked to neoplasm.